Urocit-K 15 mEq—a proven treatment for the management of1:
- Renal tubular acidosis (RTA) with calcium stones
- Hypocitraturic calcium oxalate nephrolithiasis of any etiology
- Uric acid lithiasis with or without calcium stones
Reference: 1. Urocit-K [package insert]. San Antonio, TX: Mission Pharmacal Company.
INDICATIONS: Urocit®-K (potassium citrate) is indicated for the management of renal tubular acidosis (RTA) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis with or without calcium stones.
Important Safety Information
- With hyperkalemia or in conditions associated with hyperkalemia, such as chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical activity in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown
- For whom there might be delayed tablet passage through the GI tract, e.g., gastric stasis, esophageal compression, intestinal obstruction or stricture
- With peptic ulcer disease
- With active urinary tract infection
- With renal insufficiency (GFR < 0.7 ml/kg/min)
WARNINGS AND PRECAUTIONS:
- Hyperkalemia: In patients with impaired mechanisms for excreting potassium, Urocit-K administration can produce hyperkalemia (which can develop rapidly and may be asymptomatic) and cardiac arrest. The use of Urocit-K in any condition that impairs potassium excretion (e.g., chronic renal failure, severe myocardial damage, heart failure) should be avoided. Concomitant administration of Urocit-K with potassium-sparing diuretics should also be avoided since simultaneous administration can result in severe hyperkalemia.
- Gastrointestinal lesions: If there is severe vomiting, abdominal pain, or gastrointestinal bleeding, Urocit-K should be discontinued immediately and the possibility of bowel perforation or obstruction investigated. Drugs that slow gastrointestinal transit (e.g., anticholinergics) may increase the gastrointestinal irritation produced by potassium salts.
ADVERSE REACTIONS: Adverse reactions associated with Urocit-K include minor gastrointestinal complaints such as gastrointestinal discomfort, vomiting, diarrhea, loose bowel movements, or nausea. These may be alleviated by taking the dose with meals or snacks or reducing the dosage.